Compare Digital Realty Trust, Inc. (DLR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Summit Therapeutics Inc — how do they compare? Digital Realty Trust, Inc. trades at $191.45 (market cap $70.61B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Digital Realty Trust, Inc. is far larger — about 5.9× Summit Therapeutics Inc's market cap, and Digital Realty Trust, Inc. pays a 2.56% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DLR | SMMT | |
|---|---|---|
Market Cap | $70.61B | $12.06B |
Sector | Real Estate | Health |
52-Week High | $203.91 | $26.98 |
52-Week Low | $147.93 | $12.55 |
Enterprise Value | $89.32B | $11.39B |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty (DLR) trades at $196.84, up 2.9% with bullish technical signals and strong analyst support. The stock shows robust fundamentals with revenue growth from $5.6B in 2024 to $6.1B in 2025 and net income reaching $1.31B. Recent Q2 2026 earnings beat expectations with $1.21 EPS versus $0.48 expected, driven by record leasing activity and AI-driven data center demand. The company maintains a 63.8% buy rating from analysts with a $216.56 consensus target.
DLR presents a compelling growth opportunity leveraging AI infrastructure demand, though premium valuation metrics (P/E 241.53, P/S 25.08) warrant caution. Key risks include high debt levels ($15.1B long-term) and cyclical tech spending. Current price near the $197 low target suggests limited downside with 10% upside to consensus target, supported by strong cash flow generation and dividend payments.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
